What happened
There was good news with it Moderna (NASDAQ: MRNA) Tuesday about his closely followed mRNA-1273 coronavirus vaccine candidate. However, comments from a health expert who has the ear of the nation when it comes to the pandemic eventually brought the stock down. At the end of the day, it was down more than 5%.
And then
The good news first: A briefing submitted to the Food and Drug Administration (FDA) revealed that the regulator was leaning towards approving mRNA-1273 for general use. This comes two days before the committee advising the FDA meets to discuss whether the regulator should turn on that green light.
Dr. Anthony Fauci. Image source: National Institute of Allergy and Infectious Diseases (NIAID).
However, this seemed to be overshadowed by comments previously made by high-profile expert Dr. Anthony Fauci, the director of the government’s National Institute of Allergy and Infectious Diseases (NIAID). At a health event, Fauci said about coronavirus vaccines in general that it could take a year to determine “what the durability is and whether we are dealing with something that needs to be picked up every year.”
What now
The world is both afraid and tired of the coronavirus at the same time, and it needs hope. What it doesn’t want to hear is that mRNA-based vaccines like Moderna’s are still very new on the scene and that “some form of normalcy,” according to Dr. Fauci, perhaps won’t be possible until the fall of 2021. a sober and realistic assessment, and should not be greeted as bad or unexpected news that merits a sale.